SpyGlass Pharma, Inc. (SGP)
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income | -35.71M |
| EPS | n/a |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About SGP
SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. [Read more]
News
SpyGlass Pharma Sees IPO Ahead For Its Ocular Pressure Treatment Candidates
SpyGlass Pharma is pursuing a $100 million IPO to advance its glaucoma drug delivery platform through Phase 3 trials. SGP's BIM-IOL System demonstrated a 37% mean intraocular pressure reduction at 36 ...
SpyGlass Pharma, Sustained-Release Ophthalmic Drug-Delivery Company, Files for Nasdaq Global Select Market IPO
SpyGlass Pharma filed for an initial public offering on the Nasdaq Global Select Market under the ticker SGP. The late-stage biopharmaceutical company is developing sustained-release drug-delivery sys...
SpyGlass Pharma IPO Registration Document (S-1)
SpyGlass Pharma has filed to go public with an IPO on the NASDAQ
Chronic eye condition biotech SpyGlass Pharma files for a $100 million IPO
SpyGlass Pharma, a phase 3 biotech developing implants to treat chronic eye conditions, filed on Friday with the SEC to raise up to $100 million in an initial public offering.